Pacira BioSciences' Exparel (bupivacaine liposome injectable emulsion) is protected by several patents. The earliest patent for Exparel, U.S. Patent No. 7,780,947, is set to expire on April 12, 2028 [1]. However, other patents related to Exparel's formulation and use also exist, and their expiration dates may extend further [1].
When Does Exparel's Main Patent Expire?
The primary patent covering Exparel's formulation, U.S. Patent No. 7,780,947, is scheduled to expire on April 12, 2028 [1].
Are There Other Patents Protecting Exparel?
Yes, Pacira BioSciences holds additional patents related to Exparel. These can include patents for specific manufacturing processes, methods of use, or further formulation refinements. The exact expiration dates for these secondary patents can be found through patent databases [1].
What Happens When Exparel's Patents Expire?
Upon the expiration of its key patents, Exparel will likely face competition from generic manufacturers. Companies may develop and seek approval for generic versions of Exparel, which could lead to lower prices for the drug [2]. This process often involves biosimilar or generic drug applications submitted to regulatory agencies like the U.S. Food and Drug Administration (FDA) [2].
Can Generic Versions Enter Before Patent Expiration?
Generic drug manufacturers may challenge existing patents before their expiration date through legal proceedings. Successful patent challenges or the expiration of market exclusivity can pave the way for earlier generic market entry [1][2].
How Long Has Exparel Been Available?
Exparel was approved by the FDA in October 2011 for use in the treatment of postoperative pain [3].
Who Makes Exparel?
Exparel is developed and manufactured by Pacira BioSciences, Inc. [1].
What Is Exparel Used For?
Exparel is a non-opioid analgesic used to provide post-surgical pain relief. It is injected at the surgical site during a procedure to deliver pain medication directly to the area where pain is expected [3].
What Are the Risks Associated with Exparel?
Common side effects of Exparel can include nausea, constipation, headache, fever, and vomiting. It is important for patients to discuss any potential risks and side effects with their healthcare provider [3].
Where Can I Find More Information on Drug Patents?
Detailed information on drug patents, including expiration dates and patent litigation, can be found on specialized resources such as DrugPatentWatch.com [1].
Sources
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration. (n.d.). Generic Drugs.
3. Pacira BioSciences, Inc. (n.d.). EXPAREL® (bupivacaine liposome injectable emulsion).